Central Blood Pressure Shown to Be an Independent Predictor of Cardiovascular
                              and Renal Outcomes

    DALLAS, Nov. 13 /PRNewswire-FirstCall/ -- Pfizer Inc said today that
hypertensive patients who received a treatment regimen based on Pfizer's blood
pressure lowering medicine Norvasc(R) (amlodipine besylate) had lower central
arterial blood pressure readings, which was shown to be an independent
predictor of cardiovascular and renal outcomes compared to patients who took a
beta blocker-based regimen.  The results were presented this week at the
annual meeting of the American Heart Association in Dallas.
    CAFE (Conduit Artery Function Evaluation) is a sub-study of ASCOT-BPLA
(Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm) and is
the first trial to evaluate the long-term effects of two anti-hypertensive
treatment regimens on central arterial blood pressure compared with peripheral
blood pressure measurements.  In the Norvasc-based regimen, patients received
the ACE-inhibitor perindopril and the alpha-blocker Cardura XL (doxazosin
GITS) as add-on therapy if additional blood pressure control was needed.
Patients receiving the beta-blocker based regimen of atenolol, received a
diuretic (thiazide) and Cardura XL (doxazosin GITS), if needed.
    Central arterial blood pressure is the pressure in the aorta, which
determines the stress and damage on the heart and central vessels.  Peripheral
blood pressure measurement, which is taken through the use of an arm cuff, is
widely regarded as a practical yet less precise substitute for measuring
central arterial blood pressure.
    "CAFE demonstrates for the first time in a major clinical outcomes trial
that blood pressure lowering drugs have significantly different effects on
central arterial blood pressure, despite having a similar impact on peripheral
blood pressure," said Bryan Williams, MD, professor of medicine, Department of
Cardiovascular Sciences, University of Leicester, United Kingdom.  "The
amlodipine-based regimen was shown to be more effective at lowering central
arterial blood pressure than the atenolol-based regimen.  These findings,
together with the benefits witnessed in the ASCOT study on cardiovascular and
all-cause mortality, may have significant implications for hypertension
treatment guidelines."
    The CAFE study included approximately 2,200 patients recruited from five
ASCOT-BPLA study centers in the United Kingdom and Ireland.  In CAFE, central
blood pressure was calculated from pulse pressure measurements using a well-
established methodology. Pulse pressure is the difference between systolic and
diastolic blood pressure.
    "CAFE highlights important information about the cardiovascular benefits
that are associated with different blood pressure lowering therapies," said Dr.
Michael Berelowitz, Pfizer's senior vice president of Worldwide Medical and
Outcomes Research.  "These findings provide evidence of Norvasc's ability to
effectively reduce central arterial blood pressure, which appears to be an
important and independent indicator of a patient's cardiovascular risk."
    The Norvasc-based regimen lowered central arterial blood pressure
significantly more than the atenolol-based regimen approximately 4.3 mm/Hg
lower for central systolic blood pressure and 3.0 mm/Hg lower for central
pulse pressure.  This is a clinically important difference and may help
explain the significant difference in cardiovascular outcomes in the ASCOT-
BPLA study.
    Hypertension is one of the most prevalent risk factors for cardiovascular
disease, affecting as many as 800 million people worldwide.  It is estimated
that at least 80 percent of people with high blood pressure may also have
other uncontrolled cardiovascular risk factors with elevated cholesterol being
the most common.
    The five-year ASCOT Study, which was one of the largest hypertension
trials ever conducted, involved over 19,000 patients in Europe who had high
blood pressure.  The trial compared the cardiovascular effects of a Norvasc-
based regimen versus a standard beta-blocker based regimen in reducing cardiac
events in patients with hypertension and multiple cardiovascular risk factors.
In ASCOT, patients who received the Norvasc-based regimen experienced
significant reductions in cardiovascular death, all-cause mortality and total
cardiovascular events and procedures, including heart attacks and strokes
compared to patients who received a beta blocker-based regimen.  Patients
receiving the Norvasc-based regimen also experienced a reduction in the
primary endpoint of fatal coronary heart disease and non-fatal heart attack,
which did not reach statistical significance.
    Norvasc (amlodipine besylate) is indicated for high blood pressure and
angina.  In clinical trials, the most common side effects for Norvasc versus
placebo were edema (8.3% vs 2.4%), headache (7.3% vs 7.8%), fatigue (4.5% vs
2.8%), and dizziness (3.2% vs 3.4%).
    Norvasc is a major component of Caduet (amlodipine besylate/ atorvastatin
calcium) the first single pill medicine that combines the proven blood
pressure lowering of Norvasc and the LDL-cholesterol lowering benefits of
Lipitor.  Caduet was approved by the Food and Drug Administration in February
2004.  To date, both Norvasc and Lipitor have shown to reduce the risk of
cardiovascular events.

Link to this page:

  

http://www.prnewswire.com/comp/688250.html
CONTACT:
Francisco Gebauer of Pfizer, +1-212-733-5191

---

---

Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996- PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.